Live Breaking News & Updates on Panacea Biotec Sputnik V

COVID-19: Panacea Biotec to produce 100 million doses of Sputnik V in India annually
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF.
BusinessToday.In | April 5, 2021 | Updated 21:34 IST
Panacea Biotec MD Rajesh Jain said the company will produce Sputnik V in its internationally accredited facilities.
Panacea Biotec on Monday said it has entered into an agreement with the Russian Direct Investment Fund (RDIF) to produce 100 million doses of COVID-19 vaccine Sputnik V in India annually.
Production of Sputnik V at Panacea Biotec sites will help facilitate global supply of Sputnik V to international partners of RDIF, the New-Delhi based company said in a release. Panacea Biotec has production facilities at Baddi (Himachal Pradesh), Lalru (Punjab) and Delhi. ....

Baddi Himachal Pradesh , Kirill Dmitriev , Rajesh Jain , Stelis Biopharma , Virchow Biotech Private , India Subject Expert Committee , Ministry Of Health Russia On , Russian Direct Investment Fund , Russia Gamaleya National Research Institute Of Epidemiology , Panacea Biotec , Himachal Pradesh , Gamaleya National Research Institute , Drug Controller General , Subject Expert Committee , Gland Pharma , Virchow Biotech Private Limited , Sputnik V , Biotec Rdif , Panacea Biotec Sputnik V , பாடதி இமாச்சல் பிரதேஷ் , ராஜேஷ் ஜெயின் , இந்தியா பொருள் நிபுணர் குழு , அமைச்சகம் ஆஃப் ஆரோக்கியம் ரஷ்யா ஆன் , ரஷ்ய நேரடி முதலீடு நிதி , சஞ்சீவி பயோடெக் , இமாச்சல் பிரதேஷ் ,